LASMIDITAN SUCCINATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for lasmiditan succinate and what is the scope of patent protection?
Lasmiditan succinate
is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lasmiditan succinate has eighty-five patent family members in forty-three countries.
One supplier is listed for this compound.
Summary for LASMIDITAN SUCCINATE
International Patents: | 85 |
US Patents: | 2 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 17 |
Patent Applications: | 1 |
DailyMed Link: | LASMIDITAN SUCCINATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LASMIDITAN SUCCINATE
Generic Entry Date for LASMIDITAN SUCCINATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Paragraph IV (Patent) Challenges for LASMIDITAN SUCCINATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
REYVOW | Tablets | lasmiditan succinate | 50 mg and 100 mg | 211280 | 1 | 2024-01-31 |
US Patents and Regulatory Information for LASMIDITAN SUCCINATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LASMIDITAN SUCCINATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | ⤷ Try a Trial | ⤷ Try a Trial |
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | ⤷ Try a Trial | ⤷ Try a Trial |
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LASMIDITAN SUCCINATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Costa Rica | 7496 | PIRIDINOILPIPERIDINAS COMO AGONISTAS DE 5- HT1F | ⤷ Try a Trial |
Ukraine | 124433 | ПІРИДИНОЇЛПІПЕРИДИН, ЙОГО ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ МІГРЕНІ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS) | ⤷ Try a Trial |
Ecuador | SP045317 | PIRIDINOILPIPERIDINAS COMO AGONISTAS DE 5-HT1F | ⤷ Try a Trial |
Japan | 2023123678 | ピリジノイルピペリジン5-HT1Fアゴニストに関する組成物および方法 (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS) | ⤷ Try a Trial |
Taiwan | 200306186 | Pyridinoylpiperidines as 5-HT1F agonists | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |